For the first quarter 2013, analysts estimate SNTS will generate revenues of $74.7M. On May 6th after the market close, SNTS will release the first quarter 2013 results and will BEAT the estimate. SNTS will be $21 or better! Then $30 or better... as the 2013 ends.. Then $40 or better... in early 2014... SNTS is peerless and will continue to soar and prosper!
Yahoo numbers are usually an indicator from past earnings announcements. The numbers have been upped recently to Revs at nearly $75 million for 1st quarter ($339 million for the year of 2013). If Zegerid is growing again and Uceris contributes some revenue (with good RX # growth) we should be in good shape. Looks like we owe Cosmo the milestone payment for Uceris meeting goals.
I think analysts raised numbers after investor day, slide at pag 72 is the key. I think Zegerid is flat but probably just below Q4 2012. Looking at prescription trend is difficult for me to understand.. if they are 579 Uceris is under 1M and the company probably will miss estimates. But if we have to sum them (i think we have to do it) we are at least 3M (uceris is worth 1480$/30 pills pack).